Financing, Pharma

Supernus pharma raises $30 million by royalty financing

Posted on 09 July 2014

Tags: , ,

Supernus Pharmaceuticals announced the execution of a royalty financing agreement with HealthCare Royalty Partners.

HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets by Supernus' partner United Therapeutics Corporation.

Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement.

For further deal information visit Current Agreements (subscription required)

Related

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
e80banner300x150animgif
a1banner300x150animgif